Irinotecan and Capecitabine in Treating Women With Advanced Breast Cancer
Phase 1
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2004-05-17
- Last Posted Date
- 2011-03-09
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 12
- Registration Number
- NCT00083148
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Altretamine and Etoposide in Treating Patients With HIV-Related Cancer
Phase 1
Completed
- Conditions
- LymphomaSarcoma
- First Posted Date
- 2004-05-13
- Last Posted Date
- 2013-02-04
- Lead Sponsor
- Roswell Park Cancer Institute
- Registration Number
- NCT00002936
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Porfimer Sodium in Diagnosing Patients With Head and Neck Cancer
Phase 2
Completed
- Conditions
- Head and Neck Cancer
- First Posted Date
- 2004-04-27
- Last Posted Date
- 2013-02-05
- Lead Sponsor
- Roswell Park Cancer Institute
- Registration Number
- NCT00002964
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
Phase 2
Completed
- Conditions
- Myelodysplastic SyndromesMultiple Myeloma and Plasma Cell NeoplasmGraft Versus Host DiseaseLeukemiaLymphoma
- Interventions
- Biological: anti-thymocyte globulinBiological: filgrastimProcedure: bone marrow ablation with stem cell supportProcedure: umbilical cord blood transplantationRadiation: radiation therapy
- First Posted Date
- 2004-04-27
- Last Posted Date
- 2019-12-13
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 20
- Registration Number
- NCT00003270
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Doxorubicin and Interleukin-2 in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
Phase 2
Completed
- Conditions
- Liver Cancer
- First Posted Date
- 2004-03-31
- Last Posted Date
- 2011-03-07
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 24
- Registration Number
- NCT00004248
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Photodynamic Therapy Plus Brachytherapy in Treating Patients With Lung Cancer
Phase 1
Completed
- Conditions
- Lung Cancer
- First Posted Date
- 2004-02-04
- Last Posted Date
- 2013-02-05
- Lead Sponsor
- Roswell Park Cancer Institute
- Registration Number
- NCT00014066
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Anhydrovinblastine in Treating Patients With Advanced Recurrent Solid Tumors
Phase 1
Completed
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- First Posted Date
- 2004-01-27
- Last Posted Date
- 2011-03-07
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 10
- Registration Number
- NCT00003882
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Photodynamic Therapy in Treating Patients With Early Esophageal Cancer
Phase 2
Completed
- Conditions
- Esophageal Cancer
- First Posted Date
- 2003-10-22
- Last Posted Date
- 2011-12-23
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 30
- Registration Number
- NCT00002935
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Oxaliplatin in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer
Not Applicable
Completed
- Conditions
- Colorectal Cancer
- First Posted Date
- 2003-07-08
- Last Posted Date
- 2011-03-07
- Lead Sponsor
- Roswell Park Cancer Institute
- Registration Number
- NCT00040820
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Photodynamic Therapy With HPPH in Treating Patients With Non-Small Cell Lung Cancer
Phase 1
Completed
- Conditions
- Lung Cancer
- First Posted Date
- 2003-06-25
- Last Posted Date
- 2011-03-07
- Lead Sponsor
- Roswell Park Cancer Institute
- Registration Number
- NCT00025571
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States